About UCSF Search UCSF UCSF Medical Center

I-Chow Joe Hsu, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
hsu_i-chow

Associate Professor, Department of Radiation Oncology, UCSF

Phone: (415) 353-9807 (appts, new), 353-9894 (appts, follow-up)
Box 0226, UCSF
San Francisco, CA 94143-0226

View on UCSF Profiles


Additional Websites


Education

University of Florida, Gainesville, FL, BS, 1983-87, Biochemistry
Johns Hopkins School of Med., Baltimore, MD, MD, 1987-91, Medicine
San Bernardino County Med. Ctr., SB, CA, 1991-92, Internship
Columbia-Presbyterian Med. Ctr., NY, NY, 1992-95, Residency


Professional Experience

  • 1995-1997
    Attending Physician, Radiation Oncology, California Endocurietherapy Cancer Center, Oakland CA
  • 1997-1998
    Clinical Assistant Professor, Department of Radiation Oncology, University of California San Francisco
  • 1998-2004
    Assistant Professor of Clinical Radiation Oncology, Department of Radiation Oncology, University of California, San Francisco
  • 2004-present
    Associate Professor of Clinical Radiation Oncology, Department of Radiation Oncology, University of California, San Francisco

Honors & Awards

  • 1987
    Alpha Epsilon Delta Medical Honor Society
  • 1987
    University of Florida, BS, Magna cum Laude
  • 1988, 1990
    Dean's Fund for Research, Johns Hopkins School of Medicine
  • 1989
    The John Scott McFarland Fund, Johns Hopkins School of Medicine
  • 1991
    Accolade for Outstanding Intern, San Bernardino County Hospital

Selected Publications

  1. Hsu IC, Hunt D, Straube, W, Pouliot J, Cunha A, Krishnamurthy D, Sandler H. Dosimetric Analysis of Radiation Therapy Oncology Group 0321: The Importance of Urethral Dose. Practical Radiation Oncology. 2014; 4:27-34.
    View on PubMed
  2. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):27-31.
    View on PubMed
  3. Myerson RJ, Moros EG, Diederich CJ, Haemmerich D, Hurwitz MD, Hsu IC, McGough RJ, Nau WH, Straube WL, Turner PF, Vujaskovic Z, Stauffer PR. Components of a hyperthermia clinic: Recommendations for staffing, equipment, and treatment monitoring. Int J Hyperthermia. 2014 Feb; 30(1):1-5.
    View on PubMed
  4. Crehange G, Krishnamurthy D, Cunha JA, Pickett B, Kurhanewicz J, Hsu IC, Gottschalk AR, Shinohara K, Roach M, Pouliot J. Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: Implications for focal salvage brachytherapy. Radiother Oncol. 2013 Nov; 109(2):246-50.
    View on PubMed
  5. Salgaonkar VA, Rieke V, Ozhinsky E, Prakash P, Plata J, Kurhanewicz J, Hsu IC, Diederich CJ. Model-based feasibility assessment and evaluation of prostate hyperthermia with a commercial MRI-guided endorectal high intensity focused ultrasound ablation array. J Acoust Soc Am. 2013 Nov; 134(5):4180.
    View on PubMed
  6. Pinnaduwage DS, Cunha JA, Weinberg V, Krishnamurthy D, Nash M, Hsu IC, Pouliot J. A dosimetric evaluation of using a single treatment plan for multiple treatment fractions within a given applicator insertion in gynecologic brachytherapy. Brachytherapy. 2013 Sep-Oct; 12(5):487-94.
    View on PubMed
  7. Cury FL, Hunt D, Roach M, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C. Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer. 2013 Jun 1; 119(11):1999-2004.
    View on PubMed
  8. Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013 Jun 1; 86(2):324-9.
    View on PubMed
  9. Pejavar S, Yom SS, Hwang A, Speight J, Gottschalk A, Hsu IC, Roach M, Xia P. Computer-assisted, atlas-based segmentation for target volume delineation in whole pelvic IMRT for prostate cancer. Technol Cancer Res Treat. 2013 Jun; 12(3):199-206.
    View on PubMed
  10. Siauw T, Cunha A, Berenson D, Atamturk A, Hsu IC, Goldberg K, Pouliot J. NPIP: A skew line needle configuration optimization system for HDR brachytherapy. Med Phys. 2012 Jul; 39(7):4339-46.
    View on PubMed
  11. Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Feb 1; 85(2):370-7.
    View on PubMed
  12. Abdel-Wahab M, Mahmoud O, Merrick G, Hsu IC, Arterbery VE, Ciezki JP, Frank SJ, Mohler JL, Moran BJ, Rosenthal SA, Rossi CJ, Yamada Y. ACR Appropriateness Criteria® external-beam radiation therapy treatment planning for clinically localized prostate cancer. J Am Coll Radiol. 2012 Apr; 9(4):233-8.
    View on PubMed
  13. Yamada Y, Rogers L, Demanes DJ, Morton G, Prestidge BR, Pouliot J, Cohen GN, Zaider M, Ghilezan M, Hsu IC. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy. 2012 Jan-Feb; 11(1):20-32.
    View on PubMed
  14. Moran BJ, DeRose P, Hsu IC, Abdel-Wahab M, Arterbery VE, Ciezki JP, Frank SJ, Mohler JL, Rosenthal SA, Rossi CJ, Yamada Y, Merrick GS. ACR Appropriateness Criteria® definitive external beam irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol. 2011 Dec; 34(6):636-47.
    View on PubMed
  15. Shiao SL, Sahgal A, Hu W, Jabbari S, Chuang C, Descovich M, Hsu IC, Gottschalk AR, Roach M, Ma L. Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy. Phys Med Biol. 2011 Dec 21; 56(24):7767-75.
    View on PubMed
  16. Cunha JA, Pouliot J, Weinberg V, Wang-Chesebro A, Roach M, Hsu IC. Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy. Brachytherapy. 2012 Sep-Oct; 11(5):348-53.
    View on PubMed
  17. Ciezki JP, Hsu IC, Abdel-Wahab M, Arterbery VE, Frank SJ, Mohler JL, Moran BJ, Rosenthal SA, Rossi CJ, Yamada Y, Merrick G. American College of Radiology Appropriateness Criteria(®)--locally advanced (high-risk) prostate cancer. Clin Oncol (R Coll Radiol). 2012 Feb; 24(1):43-51.
    View on PubMed
  18. Siauw T, Cunha A, Atamtürk A, Hsu IC, Pouliot J, Goldberg K. IPIP: A new approach to inverse planning for HDR brachytherapy by directly optimizing dosimetric indices. Med Phys. 2011 Jul; 38(7):4045-51.
    View on PubMed
  19. Wootton JH, Prakash P, Hsu IC, Diederich CJ. Implant strategies for endocervical and interstitial ultrasound hyperthermia adjunct to HDR brachytherapy for the treatment of cervical cancer. Phys Med Biol. 2011 Jul 7; 56(13):3967-84.
    View on PubMed
  20. American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer. Brachytherapy. 2011 Sep-Oct; 10(5):357-62.
    View on PubMed

Go to UCSF Profiles, powered by CTSI